<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35064472</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>07</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>07</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1573-7365</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>37</Volume>
            <Issue>3</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Mar</Month>
            </PubDate>
          </JournalIssue>
          <Title>Metabolic brain disease</Title>
          <ISOAbbreviation>Metab Brain Dis</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Evaluation of Styrylbenzene analog- FSB and its affinity to bind parenchymal plaques and tangles in patients of Alzheimer's disease.</ArticleTitle>
        <Pagination>
          <StartPage>639</StartPage>
          <EndPage>651</EndPage>
          <MedlinePgn>639-651</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1007/s11011-021-00885-3</ELocationID>
        <Abstract>
          <AbstractText>Although several histochemical markers for senile plaques (SP) and neurofibrillary tangles (NFTs) have been synthesized since the discovery of plaques in Alzheimer's disease (AD), only a handful of these markers stain both lesions in the human brain. Despite discovery of its ability to stain both SP and NFT over 13 years ago, the styrylbenzene derivative, (E,E)-1-fluoro-2,5-bis-(3-hydroxycarbonyl-4-hydroxy)styrylbenzene (FSB), has only recently gained attention, primarily due to its ability to function as a contrasting agent for MRI imaging of AD pathology in vivo. The structure of the compound is a nuclide with quantized angular momentum, which explains its value as a contrast agent. In the current study, modification of the established staining procedure produced meaningful improvement in the labeling of plaques and tangles in the human brain. We utilized two rodent models of AD to show FSB's value in labeling both Aβ and tau lesions. Furthermore, our current modification allows us to detect SP in rodent brains in 15 min and both SP and NFT in human brains within 20 min. The study presents new evidence regarding potential binding targets for FSB as well as optimization protocols in which various parameters have been manipulated to show how section thickness, use of frozen versus paraffin-embedded sections, and selection of staining media can affect the intensity of the plaque and tangle staining in the brain. To determine the target FSB potentially binds, we performed double immunolabeling of FSB with mOC64 (a conformational antibody that label Aβ<sub>1-42</sub>). Results indicated that all plaques in the brain colocalized with mOC64, suggesting that FSB has the potential to bind all Aβ containing plaques, making it a very sensitive detector of multiple forms of SP... All antibodies were assessed for the degree of colocalization with FSB in order to better understand potential binding targets. We found more than 90% hyperphosphorylated Tau against AT8, AT180 and S214 colocalized with FSB labeled tangles. On the other hand, more than 90% of the mOC64 containing plaques colocalized with FSB stained plaques. Our results indicate that FSB is a valuable marker that can be used to detect AD pathologies in human and rodent brains with greater fluorescence intensity relative to other conventional fluorescence markers.</AbstractText>
          <CopyrightInformation>© 2021. This is a U.S. government work and not under copyright protection in the U.S.; foreign copyright protection may apply.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Setti</LastName>
            <ForeName>Sharay E</ForeName>
            <Initials>SE</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Neurotoxicology, National Center for Toxicological Research/FDA, 3900 NCTR Rd., Jefferson, AR, 72079, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Das</LastName>
            <ForeName>Nikita</ForeName>
            <Initials>N</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Neurotoxicology, National Center for Toxicological Research/FDA, 3900 NCTR Rd., Jefferson, AR, 72079, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Raymick</LastName>
            <ForeName>James</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Neurotoxicology, National Center for Toxicological Research/FDA, 3900 NCTR Rd., Jefferson, AR, 72079, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hanig</LastName>
            <ForeName>Joseph</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Office of Regulatory Affairs, Office of Regulatory Science, Food and Drug Administration, Rockville, MD, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sarkar</LastName>
            <ForeName>Sumit</ForeName>
            <Initials>S</Initials>
            <Identifier Source="ORCID">0000-0001-6255-8809</Identifier>
            <AffiliationInfo>
              <Affiliation>Division of Neurotoxicology, National Center for Toxicological Research/FDA, 3900 NCTR Rd., Jefferson, AR, 72079, USA. Sumit.Sarkar@FDA.HHS.GOV.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>01</Month>
          <Day>22</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Metab Brain Dis</MedlineTA>
        <NlmUniqueID>8610370</NlmUniqueID>
        <ISSNLinking>0885-7490</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016874" MajorTopicYN="N">Neurofibrillary Tangles</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D058225" MajorTopicYN="Y">Plaque, Amyloid</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="Y">Amyloid beta</Keyword>
        <Keyword MajorTopicYN="Y">Histochemical tracer</Keyword>
        <Keyword MajorTopicYN="Y">Neurofibrillary tangles</Keyword>
        <Keyword MajorTopicYN="Y">Plaques</Keyword>
        <Keyword MajorTopicYN="Y">Styrylbenzene</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>8</Month>
          <Day>5</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2021</Year>
          <Month>12</Month>
          <Day>5</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>23</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>8</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>22</Day>
          <Hour>5</Hour>
          <Minute>46</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35064472</ArticleId>
        <ArticleId IdType="doi">10.1007/s11011-021-00885-3</ArticleId>
        <ArticleId IdType="pii">10.1007/s11011-021-00885-3</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Title>References</Title>
        <Reference>
          <Citation>(2020) 2020 Alzheimer's Disease Facts and Figures. [In eng]. Alzheimers Dement. https://doi.org/10.1002/alz.12068</Citation>
        </Reference>
        <Reference>
          <Citation>Espargaró A, Llabrés S, Saupe SJ, Curutchet C, Luque FJ, Sabaté R (2020) On the binding of Congo Red to amyloid fibrils. [In eng]. Angew Chem Int Ed Engl 59(21):8104–07. https://doi.org/10.1002/anie.201916630</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/anie.201916630</ArticleId>
            <ArticleId IdType="pubmed">32073233</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gong B, Radulovic M, Figueiredo-Pereira ME, Cardozo C (2016) The Ubiquitin-proteasome system: potential therapeutic targets for Alzheimer’s disease and spinal cord injury. [In English]. Review. Front Mol Neurosci 9(4). https://doi.org/10.3389/fnmol.2016.00004 . https://www.frontiersin.org/article/10.3389/fnmol.2016.00004</Citation>
        </Reference>
        <Reference>
          <Citation>Harris LD, Jasem S, Licchesi JDF (2020) The Ubiquitin system in Alzheimer’s disease. [In eng]. Adv Exp Med Biol 1233:195–221. https://doi.org/10.1007/978-3-030-38266-7_8</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/978-3-030-38266-7_8</ArticleId>
            <ArticleId IdType="pubmed">32274758</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Higuchi M, Iwata N, Matsuba Y, Sato K, Sasamoto K, Saido TC (2005) 19f and 1h Mri detection of amyloid beta plaques in vivo. [In eng]. Nat Neurosci 8(4):527–533. https://doi.org/10.1038/nn1422</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nn1422</ArticleId>
            <ArticleId IdType="pubmed">15768036</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kelenyi G (1967) Thioflavin S fluorescent and congo red anisotropic stainings in the histologic demonstration of amyloid. Acta Neuropathol 7(4): 336–348. https://www.ncbi.nlm.nih.gov/pubmed/4166287</Citation>
        </Reference>
        <Reference>
          <Citation>Mantel ML, Søbjerg LS, Huynh TH, Ebran JP, Lindhardt AT, Nielsen NC, Skrydstrup T (2008) An expedient synthesis of the fibril binding compound Fsb via sequential Pd-catalyzed coupling reactions. [In eng]. J Org Chem 73(9):3570–3573. https://doi.org/10.1021/jo7026189</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/jo7026189</ArticleId>
            <ArticleId IdType="pubmed">18363363</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sarkar S, Raymick J, Cuevas E, Rosas-Hernandez H, &amp; Hanig J (2020) Modification of methods to use Congo-red stain to simultaneously visualize amyloid plaques and tangles in human and rodent brain tissue sections. Metab Brain Dis 35(8):1371–1383</Citation>
        </Reference>
        <Reference>
          <Citation>Sato K, Higuchi M, Iwata N, Saido TC, Sasamoto K (2004) Fluoro-substituted and 13c-labeled styrylbenzene derivatives for detecting brain amyloid plaques. [In eng]. Eur J Med Chem 39(7):573–578. https://doi.org/10.1016/j.ejmech.2004.02.013</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ejmech.2004.02.013</ArticleId>
            <ArticleId IdType="pubmed">15236837</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Setti SE, Raymick J, Hanig J, Sarkar S (2021) In vivo demonstration of Congo Red labeled amyloid plaques via perfusion in the Alzheimer disease rat model. [In eng]. J Neurosci Methods 353:109082. https://doi.org/10.1016/j.jneumeth.2021.109082</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jneumeth.2021.109082</ArticleId>
            <ArticleId IdType="pubmed">33508413</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Velasco A, Fraser G, Delobel P, Ghetti B, Lavenir I, Goedert M (2008) Detection of filamentous tau inclusions by the fluorescent Congo Red derivative Fsb [(Trans, Trans)-1-Fluoro-2,5-Bis(3-Hydroxycarbonyl-4-Hydroxy)Styrylbenzene]. [In eng]. FEBS Lett 582(6):901–906. https://doi.org/10.1016/j.febslet.2008.02.025</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.febslet.2008.02.025</ArticleId>
            <ArticleId IdType="pubmed">18291106</ArticleId>
            <ArticleId IdType="pmc">2726283</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
